CSPC Pharmaceutical Group Limited (CHJTF)
USD 0.64
(3.23%)
USD 0.64
(3.23%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.14 Billion USD | -6.76% |
| 2022 | 2.3 Billion USD | 0.07% |
| 2021 | 2.3 Billion USD | 19.83% |
| 2020 | 1.92 Billion USD | 15.14% |
| 2019 | 1.66 Billion USD | 34.04% |
| 2018 | 1.24 Billion USD | 66.7% |
| 2017 | 746.41 Million USD | 54.53% |
| 2016 | 483.02 Million USD | 19.74% |
| 2015 | 403.39 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 3.49 Billion CNY | 0.0% |
| 2024 Q1 | 4.46 Billion CNY | 24.11% |
| 2023 Q2 | 1.11 Billion USD | -70.38% |
| 2023 FY | 2.14 Billion USD | -6.76% |
| 2023 Q4 | 3.59 Billion CNY | -4.64% |
| 2023 Q3 | 3.76 Billion CNY | 237.15% |
| 2023 Q1 | 3.77 Billion CNY | 246.02% |
| 2022 Q2 | 540.59 Million CNY | -16.1% |
| 2022 Q4 | 1.09 Billion USD | -72.09% |
| 2022 Q3 | 3.9 Billion CNY | 622.95% |
| 2022 Q1 | 644.36 Million CNY | 4.63% |
| 2022 FY | 2.3 Billion USD | 0.07% |
| 2021 Q4 | 615.83 Million CNY | 9.77% |
| 2021 Q2 | 543.91 Million CNY | 4.21% |
| 2021 Q3 | 561.01 Million CNY | 3.15% |
| 2021 FY | 2.3 Billion USD | 19.83% |
| 2021 Q1 | 521.92 Million CNY | 45.64% |
| 2020 FY | 1.92 Billion USD | 15.14% |
| 2020 Q4 | 358.36 Million CNY | -30.54% |
| 2020 Q3 | 515.9 Million CNY | 5.45% |
| 2020 Q2 | 489.25 Million CNY | 12.3% |
| 2020 Q1 | 435.68 Million CNY | 3.33% |
| 2019 Q4 | 421.64 Million CNY | 4.07% |
| 2019 Q3 | 405.14 Million CNY | -0.69% |
| 2019 Q2 | 407.94 Million CNY | 1.98% |
| 2019 FY | 1.66 Billion USD | 34.04% |
| 2019 Q1 | 400.02 Million CNY | 23.2% |
| 2018 FY | 1.24 Billion USD | 66.7% |
| 2018 Q4 | 324.68 Million CNY | 11.47% |
| 2018 Q1 | 299.83 Million CNY | 21.45% |
| 2018 Q3 | 291.26 Million CNY | 6.58% |
| 2018 Q2 | 273.28 Million CNY | -8.85% |
| 2017 Q2 | 164.85 Million CNY | 9.98% |
| 2017 FY | 746.41 Million USD | 54.53% |
| 2017 Q4 | 246.88 Million CNY | 28.04% |
| 2017 Q3 | 192.81 Million CNY | 16.96% |
| 2017 Q1 | 149.89 Million CNY | 15.04% |
| 2016 Q2 | 115.72 Million CNY | 9.59% |
| 2016 Q3 | 118.3 Million CNY | 2.23% |
| 2016 Q1 | 105.59 Million CNY | 0.44% |
| 2016 Q4 | 130.29 Million CNY | 10.14% |
| 2016 FY | 483.02 Million USD | 19.74% |
| 2015 FY | 403.39 Million USD | 0.0% |
| 2015 Q4 | 105.13 Million CNY | 10.67% |
| 2015 Q3 | 95 Million CNY | -5.93% |
| 2015 Q2 | 100.99 Million CNY | 8.98% |
| 2015 Q1 | 92.67 Million CNY | 8.29% |
| 2014 Q4 | 85.57 Million CNY | 5.85% |
| 2014 Q3 | 80.84 Million CNY | 3.5% |
| 2014 Q1 | 79.24 Million CNY | 13.63% |
| 2014 Q2 | 78.11 Million CNY | -1.44% |
| 2013 Q2 | 46.15 Million CNY | -27.66% |
| 2013 Q3 | 54 Million CNY | 17.0% |
| 2013 Q4 | 69.74 Million CNY | 29.14% |
| 2013 Q1 | 63.8 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AstraZeneca PLC | 29.57 Billion USD | 92.741% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.07 Billion USD | 87.423% |
| Clarus Therapeutics Holdings, Inc. | 50.96 Million USD | -4112.289% |
| Novartis AG | 24.87 Billion USD | 91.368% |
| PT Kalbe Farma Tbk. | 11823.24 Billion USD | 99.982% |